Target intelligence / Profile preview

Flagellin type B (FliC) (FliC)

Target
FliC
Molecular classification
Bacterial structural protein, Toll-like receptor 5 (TLR5) ligand, Virulence factor, Antigen
01

Overview

Flagellin type B (FliC) is the primary structural subunit of the flagellar filament in Pseudomonas aeruginosa, a major opportunistic pathogen. It is a multifunctional protein responsible for bacterial motility, chemotaxis, and initial attachment to host surfaces, which are critical steps for establishing infection [UniProt P02968]. The FliC protein is organized into domains D0, D1, D2, and D3; while D0 and D1 are highly conserved and responsible for Toll-like receptor 5 (TLR5) recognition, the D2 and D3 domains are hypervariable and project outward from the filament surface, serving as major targets for the host's adaptive immune response [PubMed: 15153205, PubMed: 11113294]. In clinical settings, Flagellin B is a key virulence factor involved in the pathogenesis of cystic fibrosis and hospital-acquired infections, as it triggers potent pro-inflammatory responses through the TLR5 and NLRC4 inflammasome pathways [PubMed: 22434327]. As a therapeutic target, the D2 subunit/domain is primarily utilized in the development of subunit vaccines and neutralizing antibodies aimed at inhibiting bacterial movement and promoting opsonophagocytosis [PubMed: 24391942]. However, the significant sequence diversity within the D2 domain across different Pseudomonas strains presents a challenge for achieving broad-spectrum efficacy [PubMed: 28863240].

Other names
Pseudomonas flagellin BB-type flagellinFliC type BFlagellar filament structural proteinD2 domain of flagellin B
02

Mechanism of action

Neutralization of motility and colonization through antibody binding; induction of protective immunity; activation of TLR5-mediated cytokine production for adjuvant effects.

03

Biological functions

Bacterial motilityChemotaxisCell adhesionBiofilm formationInnate immune response inductionTLR5 activation
04

Disease associations

Pseudomonas aeruginosa infectionCystic fibrosisVentilator-associated pneumoniaSepsisBurn wound infectionUrinary tract infection
05

Safety considerations

High antigenic variability (antigenic drift) in the D2/D3 domainsPotential for systemic inflammatory response syndrome (SIRS) if used as a systemic adjuvantStrain-specific immunity due to D2 domain hypervariability
06

Interacting drugs

IC43 (Pseudomonas vaccine candidate)

2 more in the full profile.

07

Biomarkers

Anti-flagellin B IgG titersAnti-flagellin B IgA (in sputum/mucosa)TLR5 expression levels

Beyond the preview

Go deeper on Flagellin type B (FliC) (FliC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flagellin type B (FliC) (FliC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call